<DOC>
	<DOCNO>NCT00402272</DOCNO>
	<brief_summary>The purpose Clinical Evaluation continuation assessment performance XIENCE V® Everolimus Eluting Coronary Stent System ( XIENCE V® EECSS ) treatment patient de novo coronary artery lesion .</brief_summary>
	<brief_title>SPIRIT V : Post-marketing Evaluation XIENCE V® Everolimus Eluting Coronary Stent System Europe</brief_title>
	<detailed_description>The SPIRIT V Clinical Evaluation consist two concurrent study , Diabetic Sub-Study Registry . The SPIRIT V Registry prospective , single arm , multi-center registry evaluate performance XIENCE V® EECSS real-world use , per Instruction For Use ( IFU ) . 2,700 patient enrol SPIRIT V Registry . The long term safety efficacy XIENCE V EECSS demonstrate SPIRIT FIRST trial 5 year , SPIRIT II trial 4 year , SPIRIT III Randomized Control Trial ( RCT ) 3 year . In addition , pre-approval study show low rate Target Vessel Failure Major Adverse Cardiac Events ( MACE ) observe plateau gradually decline 1 year consistently low comparator arm study . This benefit MACE sustain 5 year also independent first year result . The post approval SPIRIT V study demonstrate use XIENCE EECSS complex lesion real-world population result 1 year MACE , Stent Thrombosis Target Lesion Revascularization rate comparable previously mention pre-approval study include patient restrict inclusion / exclusion criterion . Therefore , base exist data trial , Abbott Vascular decide discontinue follow SPIRIT V Registry study 2 year .</detailed_description>
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Coronary Disease</mesh_term>
	<mesh_term>Coronary Restenosis</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<criteria>least 18 year able verbally confirm understand risk , benefit treatment alternative receive XIENCE V® EECSS he/she his/her legally authorize representative provide write informed consent prior study related procedure , approve appropriate Medical Ethics Committee respective clinical site evidence myocardial ischemia acceptable candidate coronary artery bypass graft ( CABG ) surgery undergo CIPrequired followup examination artery morphology disease suitable optimally treat maximum 4 plan XIENCE V® EESCC target lesion must de novo lesion target vessel reference diameter must 2.5 mm 4.0 mm visual estimate target lesion ≤ 28 mm length visual estimate Patient already participate another device drug study complete followup phase another study within last 30 day .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2010</verification_date>
	<keyword>drug elute stent</keyword>
	<keyword>stent</keyword>
	<keyword>Angioplasty</keyword>
	<keyword>coronary artery disease</keyword>
	<keyword>total coronary occlusion</keyword>
	<keyword>coronary artery restenosis</keyword>
	<keyword>stent thrombosis</keyword>
	<keyword>vascular disease</keyword>
	<keyword>myocardial ischemia</keyword>
	<keyword>coronary artery stenosis</keyword>
</DOC>